The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
September 25th 2023
The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
September 21st 2023
25th Annual International Lung Cancer Congress®
Register Now!
BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers
View More
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis
View More
Burst CME: Regulatory Approval Pathways for Influenza Vaccines
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
Medical Crossfire®: Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!
View More
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs
View More
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?
View More
Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult
View More
"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma
July 24th 2023Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.
Dr Patel on Safety Data and Biomarker Outcomes With Ide-Cel in High-Risk R/R Multiple Myeloma
July 21st 2023Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.
Teclistamab Snags Positive CHMP Opinion for Relapsed/Refractory Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of a Type II variation for teclistamab in the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies.
CHMP Recommends Talquetamab Monotherapy for R/R Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of talquetamab for use as a single agent in adult patients with relapsed or refractory multiple myeloma who have previously received at least 3 therapies.
Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma
July 20th 2023Nikhil C. Munshi, MD, discusses the implications of the findings from the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and the CAR T-cell therapy’s subsequent FDA approval for use in this patient population.
Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Factors in Selecting Therapy at First Relapse in Multiple Myeloma
Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
Dr Matous on the Benefit Derived from the IKEMA Trial in R/R Multiple Myeloma
July 14th 2023Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.
Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma
July 13th 2023Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.
Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care
July 11th 2023Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.
Patient Scenario: Treatment Options in MM at First Relapse
Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma
China’s National Medical Products Administration has approved the new drug application for equecabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy, including a proteasome inhibitor and an immunomodulatory drug.
Earlier Use of Ide-Cel May Increase Benefit for Patients With High-Risk R/R Myeloma
July 6th 2023Krina K. Patel, MD, MSc, expands on the importance of evaluating outcomes for treatment with ide-cel in patients with relapsed/refractory multiple myeloma with different high-risk characteristics and key findings from the high-risk subgroup analysis of the KarMMa-3 trial.
FDA Approves Ready-to-Dilute Cyclophosphamide Injection for Various Cancers
The FDA has approved a new drug application for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy in the treatment of patients with various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma
June 26th 2023Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.